Overall rank by patents
#24,476
Across all tracked assignees
USPTO PatentsView assignee record - 11 granted patents across 2 technology areas, active 2017–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61B (DIAGNOSIS; SURGERY; IDENTIFICATION).
The verdict
Harpoon holds 11 US patents across 2 technology areas, rank #24,476 of 50,000 tracked assignees.
Harpoon Medical, Inc. has been granted 11 US utility patents between 2017 and 2025, placing Harpoon Medical, Inc. at rank #24,476 across all assignees tracked by PlainPatent. This portfolio spans 2 distinct Cooperative Patent Classification (CPC) subclasses, averaging 17.0 claims per patent with primary concentration in A61B (DIAGNOSIS; SURGERY; IDENTIFICATION). As a US Corporation, Harpoon Medical, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Harpoon sits between Harbinger Motors Inc. (11 patents, rank #24,472) and Helmerich & Payne, Inc. (11 patents, rank #24,480) - the closest US assignees by grant volume. The composite Innovation Score of 29.1/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 10 grants, compared with 1 in the 2015–2019 window, a +900% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Harpoon Medical, Inc.'s 17.0 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while specialization in 2 subclasses reflects a tightly scoped invention area. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Harpoon Medical, Inc. against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
Harbinger Motors Inc.
11 patents
Hardwire, LLC
11 patents
Hario Co., Ltd.
11 patents
Harmar Mobility, LLC
11 patents
HatchTech Group B.V.
11 patents
Havah Therapeutics Pty Ltd.
11 patents
Heatscape.com, Inc.
11 patents
Helmerich & Payne, Inc.
11 patents
Harpoon Medical, Inc.
11 patents
What this shows Harpoon holds 11 patents at rank #24,476, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Harpoon's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
29 Top 70% higher than 30% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2017 | 1 | 9.1% |
| 2020 | 3 | 27.3% |
| 2021 | 2 | 18.2% |
| 2023 | 3 | 27.3% |
| 2024 | 1 | 9.1% |
| 2025 | 1 | 9.1% |
Top 2 of 2 technology areas
Overall rank by patents
#24,476
Across all tracked assignees
29.1 out of 100
How to use this portfolio
Harpoon's 11 grants land it in the top 70% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.